Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.

NCT00439413 is registered in ClinicalTrials.gov with National Institute on Drug Abuse (NIDA) as lead sponsor.

NCT NCT00439413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00439413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.
Lead sponsor
National Institute on Drug Abuse (NIDA)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
January 31, 2009
Enrollment
246 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nicotine dependence